SC
SPRO icon

Scholtz & Company’s Spero Therapeutics SPRO Stock Holding History

Scholtz & Company’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-13,810
Closed -$268K – 83
2020
Q4 		$268K Buy
13,810
+480
+4% +$7.48K 0.1% 69
2020
Q3 		$149K Buy
+13,330
New +$158K 0.07% 66

Other funds holding SPRO

ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AVAI
Atlas Venture Associates IX Boston, Massachusetts $11.8M AUM 58.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
AG
Artal Group Luxembourg $1.01B AUM 29.84% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return

Scholtz & Company's SPRO Position: Q1 2021 in Review

Scholtz & Company sold out of Spero Therapeutics (SPRO) in Q1 2021, closing a stake of 13,810 shares — an estimated $268K sold.

Scholtz & Company first reported a position in SPRO in Q3 2020 and held it in 2 quarters. The position peaked at $268K in Q4 2020. 94 funds tracked by Wall St. Rank hold SPRO as of Q1 2021.

  • Scholtz & Company reported no remaining Spero Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Scholtz & Company sold 13,810 Spero Therapeutics shares in Q1 2021, an estimated $268K.
  • Scholtz & Company first reported a position in Spero Therapeutics in Q3 2020 and held it in 2 quarters.
  • Scholtz & Company's Spero Therapeutics position peaked at $268K in Q4 2020.
  • 94 funds tracked by Wall St. Rank held Spero Therapeutics as of Q1 2021.

Based on Scholtz & Company's 13F filing for Q1 2021, filed 17 May 2021.